Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06349707
Other study ID # 2023PI112
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date April 2024
Est. completion date June 2024

Study information

Verified date April 2024
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The hypothesis was that a retrospective investigation of the molecular virological tests in a University hospital could be informative, with the aim to identify non-COVID-19 respiratory viruses during the circulation of SARS-CoV-2, according to systematic population data for public health knowledge.


Description:

The hypothesis was that a retrospective investigation of the molecular virological tests in a University hospital could be informative, with the aim to identify non-COVID-19 respiratory viruses during the circulation of SARS-CoV-2, according to systematic population data for public health knowledge: - the main goal was to perform a retrospective investigation of the molecular virological tests in a University hospital, in order to identify non-COVID-19 respiratory viruses from the beginning of 2021 to mid-2022 during the circulation of SARS-CoV-2, for public health knowledge; - the secondary aim was to retrospectively analyze, for a small subgroup of patients from an intensive care unit, the files of patients with positive molecular virological tests for non-COVID-19 respiratory viruses from the beginning of 2021 to mid-2022, reporting the following standard-of-care data: (i) the identification of the viruses, (ii) bioclinical features, (iii) medical impact of virological results in real life.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 18
Est. completion date June 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - For adult patients, or minors 'via' parents, able to give consent - 18 intensive care patients Exclusion Criteria: - Non-inclusion in case of refusal

Study Design


Intervention

Other:
other: Observational
For 18 ICU patients, retrospective collection of routine bioclinical database (ICCA db)

Locations

Country Name City State
France Schvoerer Vandoeuvre Les Nancy

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of positive viral PCR assays (not COVID-19) from hospitalizations for respiratory infections. Number of patients with positive virological molecular tests (multiplex respiratory panels) from the beginning of 2021 to mid-2022, with the nature of the viruses detected and the chronology of occurrence of positive tests. 18 months, retrospectively
Secondary Real-life features of patients in Intensive care (from the whole population - Outcome 1) with positive viral PCR during infectious pneumonia. For the group of patients in Intensive Care:
(i) number of positive molecular virological tests detecting respiratory viruses by FilmArray Pneumonia test
(ii) associated bioclinical data
(iii) medical impact of virological results in real life - progression of the infection and duration of thehospitalization.
18 months, retrospectively
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05286255 - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias Phase 1
Recruiting NCT04952337 - Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
Completed NCT04606407 - Inhaled NO for the Treatment of Viral Pneumonia in Adults N/A
Not yet recruiting NCT05612893 - Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study
Not yet recruiting NCT04397497 - Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) Phase 2
Terminated NCT04345289 - Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia Phase 3
Enrolling by invitation NCT04326036 - Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection Early Phase 1
Withdrawn NCT00645619 - Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children
Completed NCT04385823 - Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure
Not yet recruiting NCT04876573 - Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19 Phase 2
Unknown status NCT01612572 - A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals N/A
Completed NCT02152358 - PTH - Preemptive Treatment for Herpesviridae Phase 4
Completed NCT04644302 - Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis
Recruiting NCT05531149 - Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04955223 - Yinhu Qingwen Granule in the Treatment of Viral Pneumonia Early Phase 1
Completed NCT01868113 - Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial Phase 3
Recruiting NCT04380376 - Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia Phase 2
Completed NCT05386459 - Study of the Use of the Drug Ingaron in Patients With COVID-19
Completed NCT04394026 - Imaging Feature of SARS-CoV2 Infection
Not yet recruiting NCT04820751 - Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial Phase 3